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Abstract 
Background: There is evidence that physicians’ prescription behavior is negatively affected by the extent of their 
interactions with pharmaceutical companies. In order to develop and implement policies and interventions for better 
management of interactions, we need to understand physicians’ perspectives on this issue. Surveys addressing physi‑
cians’ interactions with pharmaceutical companies need to use validated tools to ensure the validity of their findings.
Objective: To assess the validity of tools used in surveys of physicians about the extent and nature of their interac‑
tions with pharmaceutical companies, and about their knowledge, beliefs and attitudes towards such interactions; 
and to identify those tools that have been formally validated.
Methods: We developed a search strategy with the assistance of a medical librarian. We electronically searched MED‑
LINE and EMBASE databases in September 2015. Teams of two reviewers conducted data selection and data abstrac‑
tion. They identified eligible studies in one table and then abstracted the relevant data from the studies with validated 
tools in another table. Tables were piloted and standardized.
Results: We identified one validated questionnaire out of the 11 assessing the nature and extent of the interaction, 
and three validated questionnaires out of the 47 assessing knowledge, beliefs and attitudes of physicians toward the 
interaction. None of these validated questionnaires were used in more than one survey.
Conclusion: The available supporting evidence of the issue of physicians’ interaction with pharmaceutical company 
is of low quality. There is a need for research to develop and validate tools to survey physicians about their interac‑
tions with pharmaceutical companies.
© 2015 Lotfi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Social, economic and public-health sectors are inter-
ested in the elements of poor prescription practices [1, 2]. 
There is evidence that physicians’ prescription behavior 
is negatively affected by the extent of their interactions 
with pharmaceutical companies [3, 4].
A large number of qualitative and quantitative studies 
aimed to understand physicians’ knowledge, beliefs and 
attitudes towards their interaction with pharmaceutical 
company representatives. In at least two studies, physi-
cians have denied being influenced by pharmaceutical 
promotion while claiming it influenced their colleagues 
[5, 6].
There have been many initiatives to manage the financial 
relationships between industry and physicians. For exam-
ple, the Institute of Medicine published in 2009 the “Conflict 
of Interest in Medical Research, Education, and Practice” 
report which included recommendations to addressing those 
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relationship [7]. More recently, the Physician Payment Sun-
shine Act has required pharmaceutical and medical device 
companies to publicly report payments to physicians and 
teaching hospitals, as well as certain ownership interests [8].
In order to develop and implement policies and inter-
ventions for better management of interactions [9], we 
need to understand their extent, as well as physicians’ 
perspectives towards interaction with pharmaceutical 
companies. Studies of physicians’ knowledge, attitudes 
and beliefs need to measure them using validated tools.
The study objectives were to:
1. Assess the validity of tools used in surveys of physicians 
about the extent and nature of their interactions with 
pharmaceutical companies, and about their knowledge, 
beliefs and attitudes of towards such interactions.




The inclusion criteria for our first objective (assessing 
validity of tools used in surveys) were:
  • Types of study design: quantitative survey studies
  • Types of participants: Practicing physicians; we used 
no restrictions on country of practice;
  • Types of interactions: any form of interaction 
between physicians and pharmaceutical companies 
or their representatives;
  • Types of outcomes: extent and nature; knowledge, 
beliefs, attitude [10].
The exclusion criteria for our first objective are:
  • Studies restricted to “residents” or “medical students”
  • Studies not published in English.
The inclusion criteria for our second objective (identi-
fying and describing validated tools) were:
  • Tools used in one of the studies included under the 
first objective
  • Tools assessed for criterion validity and/or construct 
validity (see Appendix 1 for definitions). We did not 
include tools assessed only for face and/or content 
validity given they represent perceptions and judg-
ments of experts regarding the content of the tool 
[11].
Search strategy
We developed a search strategy with the assistance of 
a medical librarian (Appendix 2). We electronically 
searched MEDLINE and EMBASE databases in Sep-
tember 2015. We did not apply any search filter. We also 
screened the references lists of included studies and the 
grey literature (e.g., theses). Last, we searched the Health 
and Psychosocial Instruments (HaPI) database to screen 
for indexed validated tools relevant to our study.
Selection of studies
Teams of two reviewers screened the titles and abstracts 
of the identified studies in duplicate and independently. 
Then they used standardized forms to screen the full 
texts of the studies judged as potentially eligible by at 
least one of the reviewers. They compared results, and 
resolved disagreement by discussion. They sought the 
input of a third reviewer as needed.
Data collection
Teams of two reviewers abstracted data from included 
studies. They compared results, and resolved disagree-
ment by discussion. When needed they sought the input 
of a third reviewer. They used pilot tested standardized 
data abstraction forms.
  • For each study included under objective 1, we noted 
whether the tool was newly developed (versus a pre-
viously developed, versus a modified version of a 
previously developed tool) and whether or not it has 
been validated.
  • For each validated tool included under objective 
2, we noted the concepts it measured (e.g., extent, 
nature, attitudes, beliefs, knowledge); how it was 
developed; and how it was validated.
Data analysis and synthesis
We calculated the kappa statistic to assess the agreement 
between reviewers for full text screening. We summa-
rized the findings in both narrative and tabular formats, 
as the nature of the data was not amenable to a meta-
analysis. We reported the results separately for tools 
measuring extent and nature, and for tools measuring 
knowledge, beliefs and attitudes.
Results
Figure  1 shows the results of the search and of study 
selection. The kappa statistic for full-text screening was 
high at 0.893. We identified 11 eligible surveys assessing 
nature and extent of the interaction, and 47 eligible sur-
veys assessing knowledge, beliefs and attitudes.
Nature and extent of the interaction
Validity of tools used in surveys
Table 1 shows the 11 included studies and the validity of 
their tools. Nine studies reported developing a new tool 
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[12–20], and two reported modifying a previously devel-
oped “validated” tool [21]. Of these 11 studies, only one 
used a tool that met our criteria for validity [19]. Of the 
remaining ten studies, three assessed content validity [18, 
20, 21].
Validated survey tools
As stated above, only one tool assessing the nature and 
extent of the interaction fit our criteria for a ‘validated 
tool’ (Table  2). That tool measured the concept of “gift 
giving”. While the report did not provide details about 
the development of the tool, it described evaluating face 
validity as well as construct validity using principal com-
ponent factor analysis of the attitudinal items.
Knowledge, beliefs and attitudes
Validity of survey tools
Table 3 categorizes the 47 included studies and the valid-
ity of their tools. Of these studies, 37 developed new 
tools, five used previously developed tools, and five 
modified previously developed tools. Of the 47 included 
studies, only three used tools that met our criteria for 
validity [2, 22, 23]. Of the remaining 40 studies, four 
studies evaluated content validity [20, 24–27] and one 
evaluated face validity [25].
Validated survey tools
Only three survey tools assessing knowledge, beliefs and 
attitudes of physicians toward the interaction met our 
eligibility criteria for a ‘validated tool’ [2, 22, 23]. Table 2 
provides a full description of those tools. In summary:
  • Concepts measured The first tool assessed the physi-
cians’ attitudes towards pharmaceutical companies 
representatives (PCRs) [22]. The second assessed 
the perspectives towards the importance of different 
“sources of influence” [2]. The third assessed physi-
cians’ attitudes toward interacting with PCRs and the 
perceptions of the effect of the value of a gift on phy-
sician’s judgment [23].
  • Development methods All three validated survey 
tools were developed based on review of literature. 
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Fig. 1 Study flow
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The first tool was additionally developed using in-
depth interviews of physicians and PCRs to develop 
a preliminary questionnaire [22]. The second [2] and 
the third [23] survey tools were developed by con-
sulting with experts while developing the question-
naire. Pre-testing was conducted for the first [22] and 
second [2] tool.
  • Types of validity Construct validity and factorial anal-
ysis were reported for the development of all three 
tools [2, 22, 23].
Discussion
In summary, the purpose of this study was to systemati-
cally review the available tools to survey physicians about 
their interactions with pharmaceutical company and 
identify the validated ones. We identified one validated 
questionnaire assessing the nature and extent of the 
interaction, and three validated questionnaires assess-
ing knowledge, beliefs and attitudes of physicians toward 
the interaction. None of these validated questionnaires 
were used in more than one survey. Four of 58 surveys on 
interactions used validated questionnaires.
The major strength of our study is the use of systematic 
review methodology (including comprehensive search, 
duplicate selection and data abstraction processes). Also, 
our systematic review is the first one to assess the valid-
ity of tools to survey physicians about their interactions 
with pharmaceutical companies. One potential limita-
tion is our restriction to physicians in practice. Although 
one could argue that questionnaires designed to survey 
residents and students might be informative and used for 
physicians, we wanted our study to be more focused.
Unfortunately, the use of non-validated or poorly vali-
dated instruments is not uncommon in health survey 
research. Indeed, we have identified three methodo-
logical studies assessing the validity of tools in specific 
healthcare fields [28–30]. The first study included stud-
ies assessing the attitudes of healthcare students and pro-
fessionals towards patients with physical disability [28]. 
This study identified 38 eligible surveys, nine of which 
used validated instruments, and only three of these fit 
our validity criteria [28]. The second methodological 
study focused on studies assessing knowledge, percep-
tions and practices of health care professionals towards 
alcoholic patients [29]. Out of 21 included studies, the 
numbers assessed for internal construct validity, external 
construct validity, and predictive validity, internal con-
sistency, and reliability were 8, 15, 1, 7 and 0 respectively 
Table 1 Description of the originality and validity of tools 
used in surveys assessing the extent and nature of interac-
tion between physicians and pharmaceutical companies
Newly developed Previously developed, 
modified
Validated Madhavan [19]










Table 2 Detailed description of validated tools used for surveying physicians about their interactions with pharmaceuti-
cal company
Study ID Concept(s) measured  
by instrument
Development methods Validation methods
Madhavan [19] Extent of giving Not described Face validity
Assessment of theoretical and construct validity  
using principal component factor analysis of 
the attitudinal items
Andaleeb [22] Attitudes toward pharmaceutical 
company representatives
Exploration of “secondary sources of informa‑
tion”
In‑depth interviews of physicians and pharma‑
ceutical company representatives
Development of a preliminary questionnaire
Pre‑testing on three physicians
Face and content validity
Construct validity
Factor analysis with correlation matrix suggest‑
ing discriminant validity
Fernandez [2] Importance of sources of influ‑
ence
Bibliographical review and assessment by 
experts
Tested on a sample of 124 GPs
Content and construct validity
Multiple correlation analysis and a factorial 
analysis
McKinney [23] Attitudes of physicians toward 
interaction with pharmaceuti‑
cal company representatives
Perception of the value of a gift 
likely to compromise a physi‑
cian’s judgment
Reviewed and edited by three individuals with 
expertise in questionnaire design, education, 
or pharmaceutical detailing
Construct validity
Expert review and factor analysis
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[29]. The third study focused on surveys of prevalence 
instruments in clinical and epidemiological research on 
waterpipe smoking [30]. Out of 38 identified surveys 
none one reported using a validated instrument [30]. The 
lack of consistent use of validated instruments could be a 
combination of substandard conduct and a substandard 
reporting of survey studies.
Conclusion
Policy makers addressing the issue of physicians’ interac-
tion with pharmaceutical company need to be aware of 
the low quality of supporting evidence due to the use of 
non-validated questionnaires (given the bias that could 
be introduced into the findings). One observation is that 
the questionnaires in the identified surveys measured 
different concepts (e.g., aspects of the interaction, “infor-
mation” or the “gifts” aspect). This limits the capacity of 
comparing results across studies (e.g., across different 
countries, or in the same country over time).
Our findings highlight the importance of the use 
by investigators of commonly accepted and validated 
instruments. These investigators could use our findings 
to choose a validated questionnaire. Unfortunately the 
choices are limited, and those investigators may reason-
ably judge that none of the instruments address exactly 
their specific research question. Therefore there is a need 
for research to develop and validate such tools. Inves-
tigators also need to adhere to suggested guidelines for 
reporting survey studies that include recommenda-
tions for reporting the extent to which the validity and 
Table 3 Description of  the originality and  validity of  tools used in  surveys assessing knowledge, beliefs and  attitudes 
of physicians towards their interaction with pharmaceutical companies
a Previously validated
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reliability of the instrument have been established [31]. It 
would also be ideal for journals to require authors of sur-
veys to adhere to those guidelines.
Abbreviation
PCR: pharmaceutical company representatives.
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Appendix 1: Types of validity
1. Content Validity: refers to evaluation of the items of 
a measure to determine whether they are representa-
tive of the domain that the measure seeks to examine. 
It is based only on the judgment of experts regarding 
the content of the items.
2. Face Validity: assumes that when we look at the ques-
tions included in a measuring instrument, it appears 
to measure the concept that it intends to measure. It 
refers to how users of the instrument perceive it.
3. Criterion Validity: establishing a correlation between 
the measure and an external criterion (a gold stand-
ard).
4. Construct Validity: the degree of measurement of 
a theoretical concept, trait, or variable; the way in 
which our construct behaves or correlates with other 
related constructs. In other words, it represents a 
framework of hypothesis testing based on the knowl-
edge of the underlying construct.
Appendix 2: Search strategies
Ovid MEDLINE(R) <1946 to August Week 4 2015>
 1. Conflict of Interest.mp. or “Conflict of Interest”/ 
(9234)
 2. Drug Industry/ (30016)
 3. Gift Giving/ (1306)
 4. detailman.mp. (4)
 5. commercial information.mp. (30)
 6. ((drug or pharma*) adj3 (industry or firm* or manu-
facture* or compan*)).mp. (40649)
 7. physician*.mp. (423538)
 8. doctor*.mp. (89855)
 9. Physicians/ (65190)
 10. primary care.mp. (72237)
 11. or/1-6 (48354)
 12. or/7-10 (522090)
 13. 11 and 12 (5684)
 14. 13 not (comment or editorial or letter).pt. (4745)
Embase <1980 to 2015 Week 36>
 1. Conflict of Interest.mp. or “Conflict of Interest”/ 
(9927)
 2. Drug Industry/ (68082)
 3. Gift Giving/ (962)
 4. detailman.mp. (3)
 5. commercial information.mp. (47)
 6. ((drug or pharma*) adj3 (industry or firm* or manu-
facture* or compan*)).mp. [mp=title, abstract, head-
ing word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade 
name, keyword] (97838)
 7. physician*.mp. (519656)
 8. doctor*.mp. (200550)
 9. Physicians/ (163052)
 10. primary care.mp. (102606)
 11. or/1-6 (106455)
 12. or/7-10 (708268)
 13. 11 and 12 (8296)
 14. 13 not (comment or editorial or letter).pt. (7157)
Appendix 3: Details of the validated tools
Madhavan surveyed physicians in West Virginia about 
their attitudes “surrounding the ‘gift relationship’ 
between pharmaceutical companies and physicians”. The 
questionnaire developed for the purpose of this study 
consisted of three sections: the first included statements 
to which physicians would indicate how much they agree 
or disagree, the second aimed to collect demographic 
information and physicians’ practice information, and 
the third asked about the amount and value of “gifts” they 
recently received. Examples from the first section: “phar-
maceutical companies give gifts to physicians to influ-
ence their prescribing”, “it is inappropriate to accept gifts 
from pharmaceutical companies” and “physician-patient 
relationship would be improved if the extent of the gift 
and receiving relationship between pharmaceutical com-
panies and physicians was made public”.
McKinney was the oldest published study (1990) 
about attitudes of physicians and residents toward their 
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“professional interaction with pharmaceutical sales rep-
resentatives”. The participants were from Minnesota and 
Wisconsin. The questionnaire they developed had two 
parts, the first asked the physicians about the potential 
ethical compromise when receiving gifts from PCRs and 
the frequency of their contact with the PCRs; the second 
included statements assessing attitudes towards PCRs 
and the physicians reported the extent of their agree-
ment with these statements. Some of these statements 
were “pharmaceutical representatives provide useful and 
accurate information about newly introduced drugs”, 
“pharmaceutical representatives should be banned from 
presentations at this institution”, “I would have the same 
degree of contact with pharmaceutical representatives 
whether or not promotional gifts were distributed” and 
“acceptance of promotional items from pharmaceuti-
cal representatives has no impact on my prescription 
behavior”.
Andaleeb [22] assessed the attitudes of physicians in 
Pennsylvania toward PCRs. They formulated the ques-
tionnaire’s items after reviewing the literature and gath-
ering information from physicians and PCRs directly, 
and then conducted in-depth interviews to identify ele-
ments explaining physicians’ attitudes. The preliminary 
questionnaire was pretested on three physicians and 
then modified. The final questionnaire included four 
subgroups and each had a statement to which physicians 
would rate their agreement to. The subgroup “favor” 
included “pharmaceutical sales representatives are an 
asset to my practice”; “support” included “pharmaceuti-
cal sales representatives provide me with information 
that helps me practice better medicine”; “Style” included 
“I feel pharmaceutical sales representatives are always 
trying to manipulate me to prescribe their company’s 
brands”; and “peers” included “the medical community 
has a negative attitude toward detail persons”.
Fernandez [2] aimed to understand the “opinion of 
general practitioners on the importance and legitimacy 
of sources of influence on medical practice”. The physi-
cians from two Spanish regions were asked to assess the 
legitimacy of different strategies and/or groups on influ-
encing medical practice: “financial incentives, politicians 
of the health field, pharmaceutical industry, scientific 
organizations, academic institutions and professional 
associations”. Another task was to rate the importance 
of different change strategies to medical practice: “infor-
mation provided by pharmaceutical companies’ visitors”, 
“attendance at training courses, reading articles and 
reports” and “existence of financial incentives”.
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